We are the combination of four hospitals: the General Hospital, the Children’s Hospital, the Women’s Hospital and the Traumatology, Rehabilitation and Burns Hospital. We are part of the Vall d’Hebron Barcelona Hospital Campus: a world-leading health park where healthcare plays a crucial role.
Patients are the centre and the core of our system. We are professionals committed to quality care and our organizational structure breaks down the traditional boundaries between departments and professional groups, with an exclusive model of knowledge areas.
Would you like to know what your stay at Vall d'Hebron will be like? Here you will find all the information.
The commitment of Vall d'Hebron University Hospital to innovation allows us to be at the forefront of medicine, providing first class care adapted to the changing needs of each patient.
Speaker: Beatriz Villafranca Magdalena, Biomedical research in gynecology (VHIR)
Endometrial cancer (EC) is the most common gynecological cancer in developed countries. Mortality rates in patients with high-risk and recurrent EC are elevated due to limited treatment options and the high chemoresistance of the tumors. The Cancer Dependency Map (DepMap) initiative aims to dramatically accelerate precision cancer medicine by systematically identifying the landscape of cancer vulnerabilities across all tumors. In this study, our goal is to identify selective dependencies in EC by genome-wide CRISPR screens using high-risk patient-derived organoid models.
For this, we selected five high-risk patient-derived endometrial cancer organoid models to perform genome-wide CRISPR viability screens. We develop methods to perform these screens using a Cas12a based library with 4 sgRNAs targeting the same genes with 2 sgRNA per construct for a total of ~20,000 genes. One of the four models screened, a uterine carcinosarcoma, was integrated with all the other screens in DepMap to identify selective dependencies. Among the identified dependencies, we selected two for which drugs are available in clinical trials, to perform drug sensitivity profiling in a larger panel of EC and non-EC organoid models. The preliminary results of the target inhibitors tested in our model seem to be promising, validating the CRISPR screen and identifying a new potential therapeutic target.
Ultimately, thanks to the inclusion of additional endometrial cancer screens, we expect to identify additional selective hits in endometrial models and enrich the landscape of potential druggable targets for endometrial cancer, approaching precision medicine of this disease.
Host: Dr. Eva Colas Ortega, Head of group Biomedical Research in Gynaecology (VHIR)
The acceptance of these terms implies that you give your consent to the processing of your personal data for the provision of the services you request through this portal and, if applicable, to carry out the necessary procedures with the administrations or public entities involved in the processing. You may exercise the mentioned rights by writing to web@vallhebron.cat, clearly indicating in the subject line “Exercise of LOPD rights”. Responsible entity: Vall d’Hebron University Hospital (Catalan Institute of Health). Purpose: Subscription to the Vall d’Hebron Barcelona Hospital Campus newsletter, where you will receive news, activities, and relevant information. Legal basis: Consent of the data subject. Data sharing: If applicable, with VHIR. No other data transfers are foreseen. No international transfer of personal data is foreseen. Rights: Access, rectification, deletion, and data portability, as well as restriction and objection to its processing. The user may revoke their consent at any time. Source: The data subject. Additional information: Additional information can be found at https://hospital.vallhebron.com/es/politica-de-proteccion-de-datos.